Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.6% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in insulin pump technology aimed at improving the lives of individuals with diabetes. The stock saw positive movement in the market today.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.6% on Jun 24, 2026 17:42

• TNDM stock surged after receiving an upgraded rating to Equal Weight from Underweight and a raised price target of $32. This improvement was attributed to an optimistic view on the company's insulin pump business, reflecting encouraging developments in the competitive landscape.
• Deutsche Bank initiated coverage on Tandem Diabetes with a Hold rating and a price target of $15.50, highlighting concerns about execution risk and complexity amid ongoing transitions. Despite recent revenue growth, analysts do not foresee profitability this year.
• The market reacted positively to the ratings upgrade from Wells Fargo, indicating investor optimism about TNDM's future performance and potential growth in the insulin pump market.
• TNDM's valuation metrics suggest room for enhancement, with a modest P/E ratio and varying analyst opinions. The company's strategic changes and product advancements could be key factors influencing its financial prospects in the upcoming quarters.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes rises on Wells Fargo upgrade

Tandem Diabetes Care (TNDM) stock rose following an upgrade from Wells Fargo. Analyst Larry Biegelsen increased the rating to Equal Weight from Underweight and raised the price target to $32 from $25, citing an improved outlook for the company's insulin pump business. The upgrade is attributed to positive changes in the competitive landscape, particularly with Insulet (PODD) and DexCom (DXCM).

http://www.msn.com/en-us/health/medical/tandem-diabetes-rises-on-wells-fargo-upgrade/ar-AA24A0sF?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Tandem Diabetes rises on Wells Fargo upgrade

Tandem Diabetes (TNDM) stock rose following an upgrade from Wells Fargo. The upgrade signals a positive outlook from the financial institution regarding the company's future performance. This news is expected to influence investor sentiment and potentially impact TNDM's market valuation.

https://www.msn.com/en-us/health/medical/tandem-diabetes-rises-on-wells-fargo-upgrade/ar-AA24A0sF

TNDM Initiated Coverage by Deutsche Bank -- Rating Set to Hold

Deutsche Bank has initiated coverage on Tandem Diabetes Care (TNDM) with a "Hold" rating and a price target of $15.50. Despite GuruFocus indicating the stock is significantly undervalued at $14.18 with a GF Value™ of $29.84, TNDM's GF Score™ of 59/100, combined with mixed analyst sentiments and low financial strength, suggests caution for investors. No insider trading activity has been reported in the past three months.

https://www.gurufocus.com/news/8927810/tndm-initiated-coverage-by-deutsche-bank-rating-set-to-hold

Deutsche Bank initiates Tandem Diabetes stock with hold rating

Deutsche Bank initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Hold rating and a price target of $15.50, citing execution risk and complexity amid multiple transitions. The company has stabilized its business, launched its smaller Mobi pump, and is transitioning to a paygo pharmacy model, which is expected to double revenue per patient compared to its legacy business. Despite recent record revenue and sales figures in Q1 2026 and expanded CE mark approval for its insulin delivery systems, analysts do not anticipate profitability this year.

https://www.investing.com/news/analyst-ratings/deutsche-bank-initiates-tandem-diabetes-stock-with-hold-rating-93CH-4755559

Tandem Diabetes Care Inc (TNDM) Valuation: PE, PB & Fair Value Analysis

Tandem Diabetes Care Inc (TNDM) has a current valuation score of 7.61, ranking 149 out of 203 in the Healthcare Equipment & Supplies industry. The article notes that the company's current P/E ratio is -10.43, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.

https://www.tradingkey.com/markets/stocks/nasdaq-tndm/company-valuation

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Up 12.6% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.7% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 10.0% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 5.5% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.2% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.6% Today

Unity Software ($U) Stock Forecast: Up 5.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.5% Today

Tandem Diabetes Care, Inc. Price History

16.05.2026 - TNDM Stock was up 5.1%

• Despite Tandem Diabetes Care's strong performance in Q1 earnings and revenue, leading to a 23.6% drop in stock value, there is speculation that market expectations did not align with the reported results.
• With a current undervaluation of 43.2% compared to the analyst price target of $29.20, investors may be driven by growth prospects, fueling the recent bullish movement.
• The 5.1% surge in TNDM shares could be linked to the company's promising growth potential, evident through a GF Score of 65/100, despite concerns surrounding financial strength and profitability.
• The positive momentum may also be influenced by advancements in the diabetes management sector, exemplified by Insulet's innovative "fully closed loop" automated insulin delivery system, which could pose a competitive edge for Tandem Diabetes Care.

18.05.2026 - TNDM Stock was down 5.8%

• The bearish movement in TNDM today could be attributed to the risk assessment highlighting higher volatility and financial risks, which might have made investors cautious.
• The notice to sell shares by insiders could have added selling pressure on the stock, signaling potential lack of confidence in the company's future performance.
• Despite the precision trading analysis indicating a positive long-term bias, the lack of dividend payouts and stock splits history might have deterred some investors looking for stable income or growth opportunities.
• Overall, the combination of risk factors, insider selling, and historical financial aspects could have contributed to the bearish sentiment surrounding TNDM today.

05.05.2026 - TNDM Stock was up 5.3%

• A recent insider trading activity involving the Chief Strategy Officer gifting shares to a family trust may have indicated confidence in the company's future outlook, contributing to favorable market sentiment.
• Tandem Diabetes Care's strategic shift in business model, efforts towards international expansion, and upcoming product launches are viewed as significant drivers for future revenue growth, appealing to investors.
• The recent allocation of Restricted Stock Units to the Chief Operating Officer may have also bolstered confidence in the leadership team's capabilities to propel the company's growth, further enhancing investor confidence.
• Despite concerns outlined in the valuation analysis, including competition and execution challenges, the overall positive developments and strategic initiatives by Tandem Diabetes Care appear to have outweighed these risks for investors, leading to the bullish market movement.

23.05.2026 - TNDM Stock was down 5.1%

• A Hold rating was initiated on Tandem Diabetes Care by Deutsche Bank due to perceived execution risks and complexities in transitions, potentially causing unease among investors.
• The company's current valuation metrics, including a low P/E ratio and undisclosed P/B, P/S, and P/CF ratios, sparked concerns regarding its financial stability and growth prospects.
• Despite positive earnings and revenue projections, the outlook emphasized fluctuations and financial risks, with a beta suggesting increased volatility, likely impacting the negative market sentiment.
• The bearish trend in Tandem Diabetes Care's stock price might have been driven by a blend of careful analyst assessments, valuation worries, and risk evaluations, shaping the overall market sentiment towards the company.

10.05.2026 - TNDM Stock was down 8.1%

• Notwithstanding Tandem Diabetes Care's recent milestones like obtaining CE mark approval in Europe for extended indications and introducing innovative products such as the Mobi Tubeless, the stock experienced a bearish trajectory today.
• The market's negative response may be attributed to concerns regarding competitive pressures and potential risks linked to global expansion.
• Some investors appear to be adopting a cautious stance on TNDM's capacity to achieve its ambitious revenue and earnings projections by 2029.
• Despite positive updates about the company, the prevailing sentiment towards Tandem Diabetes Care's stock appears to have been influenced by wider market conditions or particular investor perspectives, contributing to the downward movement in stock value.

12.05.2026 - TNDM Stock was up 5.8%

• Tandem Diabetes Care (TNDM) saw a notable increase in its stock price today driven by several positive factors:
• Encouraging results from studies on the company's fully closed loop automated insulin delivery system for Type 2 diabetes that eliminates carb-counting and insulin bolusing, leading to enhanced investor confidence.
• Obtaining CE Mark approval in Europe for expanded diabetes management indications, including pregnancy in Type 1 diabetes and adults with Type 2 diabetes, creating new market possibilities and strengthening Tandem's role in integrated diabetes care.
• Anticipation surrounding product innovations like the upcoming Mobi Tubeless launch and advancements in global expansion, promoting optimism about Tandem's future growth.
• Analysts' decision to maintain a Hold rating on Tandem Diabetes Care suggests a reserved outlook, potentially influenced by competitive market conditions despite positive company updates.
• Tandem's progress in technology, regulatory clearances, and market expansion strategies has spurred bullish activity in the stock price, indicating growing investor interest in the company's prospects within the diabetes management industry.

11.05.2026 - TNDM Stock was down 7.1%

• The company achieved CE Mark approval for expanded indications in Europe and made progress with product innovation. However, its stock trended bearishly.
• BofA Securities maintained a Hold rating and set a target price of $25, potentially impacting the lack of bullish momentum.
• Despite Tandem Diabetes Care's focus on international growth and new technological advancements, investors may be wary of competitive pressures within the diabetes management sector.
• The stock's recent positive performance and various news releases might have triggered profit-taking actions, influencing market response.

08.05.2026 - TNDM Stock was down 5.4%

• The bearish movement in TNDM stock could be attributed to a reaction by investors to recent CE mark approvals in the EU for expanded indications of its insulin pumps.
• Despite the news of expanded clearances for Tandem's insulin pumps, the market may have already priced in these developments, leading to profit-taking by traders.
• The initial market response to the expanded indications might have subsided as investors reevaluated the potential impact on Tandem's revenue and market share in the highly competitive diabetes management sector.

24.05.2026 - TNDM Stock was up 5.6%

• TNDM stock surged after receiving an upgraded rating to Equal Weight from Underweight and a raised price target of $32. This improvement was attributed to an optimistic view on the company's insulin pump business, reflecting encouraging developments in the competitive landscape.
• Deutsche Bank initiated coverage on Tandem Diabetes with a Hold rating and a price target of $15.50, highlighting concerns about execution risk and complexity amid ongoing transitions. Despite recent revenue growth, analysts do not foresee profitability this year.
• The market reacted positively to the ratings upgrade from Wells Fargo, indicating investor optimism about TNDM's future performance and potential growth in the insulin pump market.
• TNDM's valuation metrics suggest room for enhancement, with a modest P/E ratio and varying analyst opinions. The company's strategic changes and product advancements could be key factors influencing its financial prospects in the upcoming quarters.

24.05.2026 - TNDM Stock was up 6.5%

• TNDM stock rose significantly after receiving an upgrade and being initiated with a "Hold" rating by financial institutions. These positive assessments likely boosted investor confidence in the company's future prospects.
• Despite concerns about execution risk and complexity in its business transitions, Tandem Diabetes has shown stability and growth potential, with recent record revenue and sales figures in Q1 2021. This positive performance may have contributed to the bullish market movement.
• Analysts' consensus "Buy" rating and optimistic price target of $18.00, indicating a potential upside of 74.22%, could have further fueled the bullish sentiment surrounding TNDM stock.
• The company's focus on innovation, such as the launch of the smaller Mobi pump and transitioning to a paygo pharmacy model, along with anticipated revenue growth per patient, likely played a role in driving the stock's upward trajectory.

09.05.2026 - TNDM Stock was down 5.1%

• Despite recent progress in product advancements and market expansion, a bearish trend in TNDM stock today may be due to profit-taking by investors following a period of strong performance.
• The market's negative reaction could stem from concerns regarding TNDM's ability to sustain growth amidst rising competition in the diabetes management industry.
• Some investors may have anticipated more substantial announcements from Tandem Diabetes Care, leading to a minor letdown and subsequent selling pressure on the stock.

22.05.2026 - TNDM Stock was down 5.1%

• The decline in TNDM's stock price may be due to the negative EPS forecast and revenue projections for the upcoming quarter, suggesting potential challenges for the company.
• Factors such as TNDM's financial risks and volatility, as noted in the risk assessment, could have raised concerns among investors, resulting in a sell-off.
• The absence of strong long-term support signals and the heightened downside risk highlighted in trading analysis could have intensified the bearish sentiment among investors.
• In summary, the bearish market movement in TNDM today is likely a result of poor earnings forecasts, high volatility, and perceived downside risks.